5 Bracken MB et al. Methylprednisolone or naloxone 22
treatment after acute spinal cord injury: 1-year followup data. Results of the second National Acute Spinal
Cord Injury Study. J Neurosurg 1992; 76: 23–31. 23
6 Kwon BK, Tetzlaff W, Grauer JN, Beiner J, Vaccaro AR.
Pathophysiology and pharmacologic treatment of acute
spinal cord injury. Spine J 2004; 4: 451–464. 24
7 Hugenholtz H. Methylprednisolone for acute spinal cord
injury: not a standard of care. CMAJ 2003; 168:
1145–1146.
8 Blight AR. Miracles and molecules – progress in spinal
cord repair. Nat Neurosci 2002; 5(Suppl): 1051–1054. 25
9 Bethea JR, Dietrich WD. Targeting the host inflammatory response in traumatic spinal cord injury. Curr Opin
Neurol 2002; 15: 355–360. 26
10 Schwartz M, Lazarov-Spiegler O, Rapalino O, Agranov I,
Velan G, Hadani M. Potential repair of rat spinal cord
injuries using stimulated homologous macrophages.
Neurosurgery 1999; 44: 1041–1045. 27
11 Blight AR. Delayed demyelination and macrophage
invasion: a candidate for secondary cell damage in spinal
cord injury. Cent Nerv Syst Trauma 1985; 2: 299–315.
12 Shuman SL, Bresnahan JC, Beattie MS. Apoptosis of
microglia and oligodendrocytes after spinal cord contusion in rats. J Neurosci Res 1997; 50: 798–808.
13 Popovich PG. Immunological regulation of neuronal 28
degeneration and regeneration in the injured spinal cord.
Prog Brain Res 2000; 128: 43–58.
14 Jones TB et al. Passive or active immunization with
myelin basic protein impairs neurological function and
exacerbates neuropathology after spinal cord injury in 29
rats.
J Neurosci 2004; 24: 3752–3761.
15 Fitch MT, Doller C, Combs CK, Landreth GE, Silver J.
Cellular and molecular mechanisms of glial scarring and 30
progressive cavitation: in vivo and in vitro analysis of
inflammation-induced secondary injury after CNS trauma. J Neurosci 1999; 19: 8182–8198.
16 Popovich PG, Guan Z, McGaughy V, Fisher L, Hickey 31
WF, Basso DM. The neuropathological and behavioral
consequences of intraspinal microglial/macrophage activation. J Neuropathol Exp Neurol 2002; 61: 623–633.
17 Popovich PG, Guan Z, Wei P, Huitinga I, van Rooijen N, 32
Stokes BT. Depletion of hematogenous macrophages
promotes partial hindlimb recovery and neuroanatomical 33
repair after experimental spinal cord injury. Exp Neurol
1999; 158: 351–365.
18 Stirling DP et al. Minocycline treatment reduces delayed
oligodendrocyte death, attenuates axonal dieback, and 34
improves functional outcome after spinal cord injury.
J Neurosci 2004; 24: 2182–2190.
19 Wells JE, Hurlbert RJ, Fehlings MG, Yong VW.
Neuroprotection by minocycline facilitates significant 35
recovery from spinal cord injury in mice. Brain 2003;
126: 1628–1637.
20 McPhail LT, Stirling DP, Tetzlaff W, Kwiecien JM, 36
Ramer MS. The contribution of activated phagocytes
and myelin degeneration to axonal retraction/dieback
following spinal cord injury. Eur J Neurosci 2004; 20: 37
1984–1994.
21 Teng YD et al. Minocycline inhibits contusion-triggered
mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc Natl Acad Sci 38
USA 2004; 101: 3071–3076.
